Isoniazid for tremor in multiple sclerosis: a controlled trial

Neurology. 1985 Dec;35(12):1772-5. doi: 10.1212/wnl.35.12.1772.

Abstract

We evaluated the effects of isoniazid on tremor in 13 patients with MS. Patients were evaluated before treatment, after 1 month of therapy (1,000 mg daily), and 1 month after the last dose. Ten patients improved on at least one of three methods of evaluation. Transient side effects were common, possibly because there was a high percentage of "slow acetylators"; dosage was reduced by one-half in five patients. Improvement was mild and did not result in significant functional improvement.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Clinical Trials as Topic
  • Female
  • Humans
  • Isoniazid / adverse effects
  • Isoniazid / therapeutic use*
  • Male
  • Middle Aged
  • Multiple Sclerosis / drug therapy*
  • Tremor / drug therapy*

Substances

  • Isoniazid